Payden & Rygel’s Amgen AMGN Stock Holding History

Payden & Rygel’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,300	Closed	-$1.48M	–	114
2025 Q2	$1.48M	Hold	5,300	–	–	0.12%	74
2025 Q1	$1.65M	Hold	5,300	–	–	0.14%	77
2024 Q4	$1.38M	Sell	5,300 -30,100	-85%	-$8.93M	0.12%	79
2024 Q3	$11.4M	Buy	35,400 +200	+0.6%	+$65.4K	0.88%	58
2024 Q2	$11M	Sell	35,200 -22,700	-39%	-$6.67M	0.89%	59
2024 Q1	$16.5M	Buy	57,900 +52,600	+992%	+$15.4M	0.78%	44
2023 Q4	$1.53M	Hold	5,300	–	–	0.11%	89
2023 Q3	$1.42M	Buy	+5,300	New	+$1.32M	0.1%	92
2023 Q2	–	Sell	-70,540	Closed	-$17.1M	–	132
2023 Q1	$17.1M	Buy	70,540 +69,440	+6,313%	+$17M	1.01%	49
2022 Q4	$289K	Hold	1,100	–	–	0.02%	116
2022 Q3	$248K	Hold	1,100	–	–	0.01%	115
2022 Q2	$268K	Hold	1,100	–	–	0.02%	114
2022 Q1	$266K	Sell	1,100 -101,040	-99%	-$23.2M	0.01%	110
2021 Q4	$23M	Sell	102,140 -33,700	-25%	-$7.11M	1.06%	50
2021 Q3	$28.9M	Buy	135,840 +3,800	+3%	+$875K	1.5%	23
2021 Q2	$32.2M	Sell	132,040 -2,300	-2%	-$566K	1.53%	21
2021 Q1	$33.4M	Buy	134,340 +2,050	+2%	+$489K	1.55%	21
2020 Q4	$30.4M	Hold	132,290	–	–	1.56%	28
2020 Q3	$33.6M	Buy	132,290 +53,440	+68%	+$13.2M	1.99%	15
2020 Q2	$18.6M	Buy	78,850 +1,700	+2%	+$388K	1.19%	47
2020 Q1	$15.6M	Buy	77,150 +76,500	+11,769%	+$16.7M	1.13%	45
2019 Q4	$157K	Hold	650	–	–	0.01%	92
2019 Q3	$126K	Sell	650 -12,680	-95%	-$2.43M	0.01%	90
2019 Q2	$2.46M	Hold	13,330	–	–	0.17%	62
2019 Q1	$2.53M	Sell	13,330 -128,600	-91%	-$24.6M	0.18%	64
2018 Q4	$27.6M	Buy	141,930 +12,980	+10%	+$2.53M	2.23%	9
2018 Q3	$26.7M	Sell	128,950 -6,500	-5%	-$1.28M	2.04%	11
2018 Q2	$25M	Buy	135,450 +400	+0.3%	+$70.8K	1.97%	16
2018 Q1	$23M	Buy	135,050 +37,700	+39%	+$6.92M	1.87%	17
2017 Q4	$16.9M	Buy	97,350 +13,500	+16%	+$2.39M	1.47%	28
2017 Q3	$15.6M	Hold	83,850	–	–	1.55%	26
2017 Q2	$14.4M	Hold	83,850	–	–	1.26%	30
2017 Q1	$13.8M	Hold	83,850	–	–	1.26%	35
2016 Q4	$12.3M	Buy	83,850 +83,200	+12,800%	+$12.5M	1.13%	41
2016 Q3	$108K	Hold	650	–	–	0.01%	78
2016 Q2	$99K	Hold	650	–	–	0.01%	81
2016 Q1	$97K	Hold	650	–	–	0.01%	82
2015 Q4	$106K	Hold	650	–	–	0.01%	87
2015 Q3	$90K	Hold	650	–	–	0.01%	92
2015 Q2	$100K	Hold	650	–	–	0.01%	91
2015 Q1	$104K	Hold	650	–	–	0.01%	94
2014 Q4	$104K	Hold	650	–	–	0.02%	86
2014 Q3	$91K	Hold	650	–	–	0.02%	95
2014 Q2	$77K	Hold	650	–	–	0.02%	105
2014 Q1	$80K	Hold	650	–	–	0.03%	97
2013 Q4	$74K	Hold	650	–	–	0.03%	136
2013 Q3	$73K	Hold	650	–	–	0.03%	123
2013 Q2	$64K	Buy	+650	New	+$67.5K	0.03%	125

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Payden & Rygel's AMGN Position: Q3 2025 in Review

Payden & Rygel sold out of Amgen (AMGN) in Q3 2025, closing a stake of 5,300 shares — an estimated $1.48M sold.

Payden & Rygel first reported a position in AMGN in Q2 2013 and held it in 48 quarters. The position peaked at $33.6M in Q3 2020. 2,819 funds tracked by Wall St. Rank hold AMGN as of Q3 2025.

Payden & Rygel reported no remaining Amgen position as of Q3 2025 after selling out during the quarter.
Payden & Rygel sold 5,300 Amgen shares in Q3 2025, an estimated $1.48M.
Payden & Rygel first reported a position in Amgen in Q2 2013 and held it in 48 quarters.
Payden & Rygel's Amgen position peaked at $33.6M in Q3 2020.
2,819 funds tracked by Wall St. Rank held Amgen as of Q3 2025.

Based on Payden & Rygel's 13F filing for Q3 2025, filed 10 Nov 2025.